VBL presents positive preclinical data The immunomodulator in rheumatoid arthritis EULAR Annual Meeting VBL Therapeutics, a biotechnology company-phase clinic committed to the development of new treatments for inflammatory immune diseases and cancer, announced preclinical data demonstrating that has VB-201 anti-inflammatory properties and effectively reduced the symptoms of arthritis in experimental models. These results were presented today at the European League Against Rheumatism …
psoriasis information